Advertisement

Instructive Cases of Pulmonary Sarcoidosis

  • Andrew J. GoodwinEmail author
  • Carlos E. Kummerfeldt
Chapter
  • 1.4k Downloads
Part of the Respiratory Medicine book series (RM, volume 17)

Abstract

The respiratory system is the organ system most commonly affected by sarcoidosis. The most common finding is mediastinal and/or hilar lymphadenopathy, however involvement of the upper and lower airways, lung parenchyma, and pulmonary vasculature are also seen with varying frequencies. This chapter utilizes a case-based format in order to highlight different presentations of pulmonary sarcoidosis with which clinicians should be familiar. The accompanying discussions are designed to review the existing literature regarding each presentation as well as provide a historical view of pulmonary sarcoidosis for the practicing clinician. While there are many different presentations of pulmonary sarcoidosis that could have been discussed here, these cases were selected specifically for their instructive potential and not because of their frequency. Our hope is that these cases will enhance clinicians’ understanding of different pulmonary sarcoidosis presentations as well as improve their comfort level with the management of this disease.

Keywords

Respiratory system Mediastinal lymphadenopathy Hilar lymphadenopathy Lung parenchyma Pulmonary vasculature 

References

  1. 1.
    Hutchinson J, editor. Anomalous diseases of skin and fingers: case of livid papillary psoriasis? Illustrations of clinical surgery. London: J and A Churchill; 1877.Google Scholar
  2. 2.
    Austrian R, McClement JH, Renzetti Jr AD, Donald KW, Riley RL, Cournand A. Clinical and physiologic features of some types of pulmonary diseases with impairment of alveolar-capillary diffusion; the syndrome of “alveolar-capillary block”. Am J Med. 1951;11(6):667–85.PubMedGoogle Scholar
  3. 3.
    Handa T, Nagai S, Miki S, Fushimi Y, Ohta K, Mishima M, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest. 2006;129(5): 1246–52.PubMedGoogle Scholar
  4. 4.
    Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest. 2005;128(3):1483–9.PubMedGoogle Scholar
  5. 5.
    Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005;25(5):783–8.PubMedGoogle Scholar
  6. 6.
    Nunes H, Humbert M, Capron F, Brauner M, Sitbon O, Battesti JP, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax. 2006;61(1):68–74.PubMedGoogle Scholar
  7. 7.
    Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S43–54.PubMedGoogle Scholar
  8. 8.
    Shigemitsu H, Nagai S, Sharma OP. Pulmonary hypertension and granulomatous vasculitis in sarcoidosis. Curr Opin Pulm Med. 2007;13(5):434–8.PubMedGoogle Scholar
  9. 9.
    Salazar A, Mana J, Sala J, Landoni BR, Manresa F. Combined portal and pulmonary hypertension in sarcoidosis. Respiration. 1994;61(2):117–9.PubMedGoogle Scholar
  10. 10.
    Turner GA, Lower EE, Corser BC, Gunther KL, Baughman RP. Sleep apnea in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14(1):61–4.PubMedGoogle Scholar
  11. 11.
    Damuth TE, Bower JS, Cho K, Dantzker DR. Major pulmonary artery stenosis causing pulmonary hypertension in sarcoidosis. Chest. 1980;78(6):888–91.PubMedGoogle Scholar
  12. 12.
    Morawiec E, Hachulla-Lemaire AL, Chabrol J, Remy-Jardin M, Wallaert B. Venoatrial compression by lymphadenopathy in sarcoidosis. Eur Respir J. 2010;35(5):1188–91.PubMedGoogle Scholar
  13. 13.
    Hamilton-Craig CR, Slaughter R, McNeil K, Kermeen F, Walters DL. Improvement after angioplasty and stenting of pulmonary arteries due to sarcoid mediastinal fibrosis. Heart Lung Circ. 2009;18(3):222–5.PubMedGoogle Scholar
  14. 14.
    Toonkel RL, Borczuk AC, Pearson GD, Horn EM, Thomashow BM. Sarcoidosis-associated fibrosing mediastinitis with resultant pulmonary hypertension: a case report and review of the literature. Respiration. 2010;79(4):341–5.PubMedGoogle Scholar
  15. 15.
    Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129(3):746–52.PubMedGoogle Scholar
  16. 16.
    Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med. 1972;286(17):912–8.PubMedGoogle Scholar
  17. 17.
    Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981;36(10):752–8.PubMedGoogle Scholar
  18. 18.
    Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am Rev Respir Dis. 1979;119(6):895–902.PubMedGoogle Scholar
  19. 19.
    Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest. 2010;138(5):1078–85.PubMedGoogle Scholar
  20. 20.
    Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest. 2003;124(3):922–8.PubMedGoogle Scholar
  21. 21.
    Arcasoy SM, Christie JD, Pochettino A, Rosengard BR, Blumenthal NP, Bavaria JE, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest. 2001;120(3):873–80.PubMedGoogle Scholar
  22. 22.
    Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J. 2008;32(2):296–302.PubMedGoogle Scholar
  23. 23.
    Tan RT, Kuzo R, Goodman LR, Siegel R, Haasler GB, Presberg KW. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Medical College of Wisconsin Lung Transplant Group. Chest. 1998;113(5):1250–6.PubMedGoogle Scholar
  24. 24.
    Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003;167(5):735–40.PubMedGoogle Scholar
  25. 25.
    James DG, Sharma OP. From Hutchinson to now: a historical glimpse. Curr Opin Pulm Med. 2002;8(5):416–23.PubMedGoogle Scholar
  26. 26.
    Bessnier E. Lupus Pernio de la Face. Ann Derm Syph. 1889;10:33–6.Google Scholar
  27. 27.
    Boeck C. Multiple benign sarcoid of the skin. Norsk Mag Laegevid. 1899;14:1321–45.Google Scholar
  28. 28.
    Heerfordt CF. Meber eine “Febris uveo-parotidea subchronica Graefes Arch”. Clin Exp Ophthalmol. 1909;70:254.Google Scholar
  29. 29.
    Loncope W, Pierson J. Boeck’s sarcoid (sarcoidosis). Bull Johns Hopkins Hosp. 1937;60: 223–96.Google Scholar
  30. 30.
    Pautrier L. Syndrome de Heerfordt et maladie de Besnier-Boeck-Schaumann. Bull Soc Med Hop Paris. 1937;53:1608–20.Google Scholar
  31. 31.
    Schaumann J. Lymphogranuloma benigna in the light of prolonged clinical observations and autopsy findings. Br J Dermatol. 1936;48:399.Google Scholar
  32. 32.
    Lofgren S. Primary pulmonary sarcoidosis. I. Early signs and symptoms. Acta Med Scand. 1953;145(6):424–31.PubMedGoogle Scholar
  33. 33.
    Lofgren S. Primary pulmonary sarcoidosis. II. Clinical course and prognosis. Acta Med Scand. 1953;145(6):465–74.PubMedGoogle Scholar
  34. 34.
    Riley EA. Boeck’s sarcoid; a review based upon a clinical study of fifty-two cases. Am Rev Tuberc. 1950;62(3):231–85.PubMedGoogle Scholar
  35. 35.
    Scadding JG. Mycobacterium tuberculosis in the aetiology of sarcoidosis. Br Med J. 1960;2(5213):1617–23.PubMedGoogle Scholar
  36. 36.
    Emerson PA, Young FH. Sarcoidosis following tuberculosis. Tubercle. 1956;37(2):116–9.PubMedGoogle Scholar
  37. 37.
    Lees AW. Transition from open pulmonary tuberculosis to sarcoidosis. Am Rev Tuberc. 1958;78(5):769–72.PubMedGoogle Scholar
  38. 38.
    Hatzakis K, Siafakas NM, Bouros D. Miliary sarcoidosis following miliary tuberculosis. Respiration. 2000;67(2):219–22.PubMedGoogle Scholar
  39. 39.
    Rutherford RM, Gilmartin JJ. A case of sarcoidosis following exposure to Mycobacterium tuberculosis (MTb). Ir Med J. 2003;96(2):58–9.PubMedGoogle Scholar
  40. 40.
    Luk A, Lee A, Ahn E, Soor GS, Ross HJ, Butany J. Cardiac sarcoidosis: recurrent disease in a heart transplant patient following pulmonary tuberculosis infection. Can J Cardiol. 2010;26(7):e273–5.PubMedGoogle Scholar
  41. 41.
    Ganguly S, Ganguly D. Sarcoidosis following sputum positive pulmonary tuberculosis: a rare entity. Indian J Dermatol. 2012;57(1):76–8.PubMedGoogle Scholar
  42. 42.
    Taylor AJ. The association of sarcoidosis, active pulmonary tuberculosis and insensitivity to tuberculin. Br J Tuberc Dis Chest. 1958;52(1):70–3.PubMedGoogle Scholar
  43. 43.
    Giotaki HA, Stefanou DG. Biopsy-documented tuberculous pleural effusion in a patient with biopsy-proven coexisting sarcoidosis. Respiration. 1988;54(3):193–6.PubMedGoogle Scholar
  44. 44.
    Wong CF, Yew WW, Wong PC, Lee J. A case of concomitant tuberculosis and sarcoidosis with mycobacterial DNA present in the sarcoid lesion. Chest. 1998;114(2):626–9.PubMedGoogle Scholar
  45. 45.
    Oluboyo PO, Awotedu AA, Banach L. Concomitant sarcoidosis in a patient with tuberculosis: first report of association in Africa. Cent Afr J Med. 2005;51(11-12):123–5.PubMedGoogle Scholar
  46. 46.
    Greally JF, Manning D, McNicholl B. Sarcoidosis following B.C.G. vaccination in a lymphopaenic boy. Sarcoidosis. 1989;6(2):156–7.PubMedGoogle Scholar
  47. 47.
    el-Zaatari FA, Naser SA, Markesich DC, Kalter DC, Engstand L, Graham DY. Identification of Mycobacterium avium complex in sarcoidosis. J Clin Microbiol. 1996;34(9):2240–5.PubMedGoogle Scholar
  48. 48.
    Osborne GE, Mallon E, Mayou SC. Juvenile sarcoidosis after BCG vaccination. J Am Acad Dermatol. 2003;48(5 Suppl):S99–102.PubMedGoogle Scholar
  49. 49.
    Terzian C, Rahal JJ. Mycobacterial infection as a precursor to sarcoid-like, corticosteroid-responsive, diffuse granulomatous disease. Int J Infect Dis. 2006;10(5):407–8.PubMedGoogle Scholar
  50. 50.
    Saboor SA, Johnson NM, McFadden J. Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Lancet. 1992;339(8800):1012–5.PubMedGoogle Scholar
  51. 51.
    Schick U, May A, Schwarz M. Detection of mycobacterial DNA in a patient with neurosarcoidosis. Acta Neurol Scand. 1995;91(4):280–2.PubMedGoogle Scholar
  52. 52.
    Richter E, Greinert U, Kirsten D, Rusch-Gerdes S, Schluter C, Duchrow M, et al. Assessment of mycobacterial DNA in cells and tissues of mycobacterial and sarcoid lesions. Am J Respir Crit Care Med. 1996;153(1):375–80.PubMedGoogle Scholar
  53. 53.
    el-Zaatari FA, Graham DY, Samuelsson K, Engstrand L. Detection of Mycobacterium avium complex in cerebrospinal fluid of a sarcoid patient by specific polymerase chain reaction assays. Scand J Infect Dis. 1997;29(2):202–4.PubMedGoogle Scholar
  54. 54.
    Brownell I, Ramirez-Valle F, Sanchez M, Prystowsky S. Evidence for mycobacteria in sarcoidosis. Am J Respir Cell Mol Biol. 2011;45(5):899–905.PubMedGoogle Scholar
  55. 55.
    Song Z, Marzilli L, Greenlee BM, Chen ES, Silver RF, Askin FB, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. 2005;201(5):755–67.PubMedGoogle Scholar
  56. 56.
    Dubaniewicz A, Dubaniewicz-Wybieralska M, Sternau A, Zwolska Z, Izycka-Swieszewska E, Augustynowicz-Kopec E, et al. Mycobacterium tuberculosis complex and mycobacterial heat shock proteins in lymph node tissue from patients with pulmonary sarcoidosis. J Clin Microbiol. 2006;44(9):3448–51.PubMedGoogle Scholar
  57. 57.
    Oswald-Richter KA, Beachboard DC, Zhan X, Gaskill CF, Abraham S, Jenkins C, et al. Multiple mycobacterial antigens are targets of the adaptive immune response in pulmonary sarcoidosis. Respir Res. 2010;11:161.PubMedGoogle Scholar
  58. 58.
    Carlisle J, Evans W, Hajizadeh R, Nadaf M, Shepherd B, Ott RD, et al. Multiple Mycobacterium antigens induce interferon-gamma production from sarcoidosis peripheral blood mononuclear cells. Clin Exp Immunol. 2007;150(3):460–8.PubMedGoogle Scholar
  59. 59.
    Ishige I, Usui Y, Takemura T, Eishi Y. Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet. 1999;354(9173): 120–3.PubMedGoogle Scholar
  60. 60.
    Ichikawa H, Kataoka M, Hiramatsu J, Ohmori M, Tanimoto Y, Kanehiro A, et al. Quantitative analysis of propionibacterial DNA in bronchoalveolar lavage cells from patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25(1):15–20.PubMedGoogle Scholar
  61. 61.
    Ishige I, Eishi Y, Takemura T, Kobayashi I, Nakata K, Tanaka I, et al. Propionibacterium acnes is the most common bacterium commensal in peripheral lung tissue and mediastinal lymph nodes from subjects without sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(1):33–42.PubMedGoogle Scholar
  62. 62.
    Tanabe T, Ishige I, Suzuki Y, Aita Y, Furukawa A, Ishige Y, et al. Sarcoidosis and NOD1 variation with impaired recognition of intracellular Propionibacterium acnes. Biochim Biophys Acta. 2006;1762(9):794–801.PubMedGoogle Scholar
  63. 63.
    Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170(12):1324–30.PubMedGoogle Scholar
  64. 64.
    Laney AS, Cragin LA, Blevins LZ, Sumner AD, Cox-Ganser JM, Kreiss K, et al. Sarcoidosis, asthma, and asthma-like symptoms among occupants of a historically water-damaged office building. Indoor Air. 2009;19(1):83–90.PubMedGoogle Scholar
  65. 65.
    Tercelj M, Salobir B, Harlander M, Rylander R. Fungal exposure in homes of patients with sarcoidosis – an environmental exposure study. Environ Health. 2011;10(1):8.PubMedGoogle Scholar
  66. 66.
    Tercelj M, Salobir B, Zupancic M, Rylander R. Antifungal medication is efficient in the treatment of sarcoidosis. Ther Adv Respir Dis. 2011;5(3):157–62.PubMedGoogle Scholar
  67. 67.
    Buck AA, Sartwell PE. Epidemiologic investigations of sarcoidosis. II. Skin sensitivity and environmental factors. Am J Hyg. 1961;74:152–73.PubMedGoogle Scholar
  68. 68.
    Terris M, Chaves AD. An epidemiologic study of sarcoidosis. Am Rev Respir Dis. 1966; 94(1):50–5.PubMedGoogle Scholar
  69. 69.
    Cummings MM, Hudgins PC. Chemical constituents of pine pollen and their possible relationship to sarcoidosis. Am J Med Sci. 1958;236(3):311–7.PubMedGoogle Scholar
  70. 70.
    Burdick KH. Cutaneous reaction to pine pollen in sarcoidosis. Study of forty cases. J Invest Dermatol. 1964;42:449–51.PubMedGoogle Scholar
  71. 71.
    Gentry JT, Nitowsky HM, Michael Jr M. Studies on the epidemiology of sarcoidosis in the United States: the relationship to soil areas and to urban-rural residence. J Clin Invest. 1955;34(12):1839–56.PubMedGoogle Scholar
  72. 72.
    Hurley HJ, Close HP, English RS. Soil extracts as antigens in sarcoidosis. Am Rev Respir Dis. 1962;86:100–2.PubMedGoogle Scholar
  73. 73.
    Teuber SS, Howell LP, Yoshida SH, Gershwin ME. Remission of sarcoidosis following removal of silicone gel breast implants. Int Arch Allergy Immunol. 1994;105(4):404–7.PubMedGoogle Scholar
  74. 74.
    Yoshida T, Tanaka M, Okamoto K, Hirai S. Neurosarcoidosis following augmentation mammoplasty with silicone. Neurol Res. 1996;18(4):319–20.PubMedGoogle Scholar
  75. 75.
    Barzo P, Tamasi L. [Lofgren syndrome after silicone breast prosthesis implantation]. Orv Hetil. 1998;139(39):2323–6.PubMedGoogle Scholar
  76. 76.
    Miyashita T, Yoshioka K, Nakamura T, Yamagami K. A case of sarcoidosis with unusual radiographic findings that developed 5 years after silicone augmentation mammoplasty complicated by miliary tuberculosis during corticosteroid treatment. Case Rep Pulmonol. 2011;2011:268620.PubMedGoogle Scholar
  77. 77.
    Pimentel L, Barnadas M, Vidal D, Sancho F, Fontarnau R, Alomar A. Simultaneous presentation of silicone and silica granuloma: a case report. Dermatology. 2002;205(2):162–5.PubMedGoogle Scholar
  78. 78.
    Andrews TR, Calamia KT, Waldorf JC, Walsh JS. Subcutaneous nodules on the face – quiz case. Arch Dermatol. 2005;141(1):93–8.PubMedGoogle Scholar
  79. 79.
    Kogushi H, Egawa K, Ono T. Sarcoidal granuloma developing not only at the entry site of industrial lubricating oil, but also at a regional lymph node and entry points of venepuncture. Dermatology. 2006;212(3):250–2.PubMedGoogle Scholar
  80. 80.
    Descamps V, Landry J, Frances C, Marinho E, Ratziu V, Chosidow O. Facial cosmetic filler injections as possible target for systemic sarcoidosis in patients treated with interferon for chronic hepatitis C: two cases. Dermatology. 2008;217(1):81–4.PubMedGoogle Scholar
  81. 81.
    Stroh C, Bottger J, Meyer F, Lippert H, Manger T. Sarcoidosis after adjustable silicone gastric banding – a report of two cases in Germany. Obes Facts. 2009;2(5):332–4.PubMedGoogle Scholar
  82. 82.
    Kim YC, Triffet MK, Gibson LE. Foreign bodies in sarcoidosis. Am J Dermatopathol. 2000;22(5):408–12.PubMedGoogle Scholar
  83. 83.
    Izbicki G, Chavko R, Banauch GI, Weiden MD, Berger KI, Aldrich TK, et al. World Trade Center “sarcoid-like” granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest. 2007;131(5):1414–23.PubMedGoogle Scholar
  84. 84.
    Crowley LE, Herbert R, Moline JM, Wallenstein S, Shukla G, Schechter C, et al. “Sarcoid like” granulomatous pulmonary disease in World Trade Center disaster responders. Am J Ind Med. 2011;54(3):175–84.PubMedGoogle Scholar
  85. 85.
    Bowers B, Hasni S, Gruber BL. Sarcoidosis in World Trade Center rescue workers presenting with rheumatologic manifestations. J Clin Rheumatol. 2010;16(1):26–7.PubMedGoogle Scholar
  86. 86.
    Jordan HT, Stellman SD, Prezant D, Teirstein A, Osahan SS, Cone JE. Sarcoidosis diagnosed after September 11, 2001, among adults exposed to the World Trade Center disaster. J Occup Environ Med Sep. 2011;53(9):966–74.Google Scholar
  87. 87.
    Newman LS. Metals that cause sarcoidosis. Semin Respir Infect. 1998;13(3):212–20.PubMedGoogle Scholar
  88. 88.
    Deubelbeiss U, Gemperli A, Schindler C, Baty F, Brutsche MH. Prevalence of sarcoidosis in Switzerland is associated with environmental factors. Eur Respir J. 2010;35(5):1088–97.PubMedGoogle Scholar
  89. 89.
    Checchi L, Nucci MC, Gatti AM, Mattia D, Violante FS. Sarcoidosis in a dental surgeon: a case report. J Med Case Rep. 2010;4:259.PubMedGoogle Scholar
  90. 90.
    Kawano-Dourado LB, Carvalho CR, Santos UP, Canzian M, Coletta EN, Pereira CA, et al. Tunnel excavation triggering pulmonary sarcoidosis. Am J Ind Med. 2012;55(4):390–4.PubMedGoogle Scholar
  91. 91.
    Song Y, Li X, Wang L, Rojanasakul Y, Castranova V, Li H, et al. Nanomaterials in humans: identification, characteristics, and potential damage. Toxicol Pathol. 2011;39(5):841–9.PubMedGoogle Scholar
  92. 92.
    Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med. 2001;164(11):2085–91.PubMedGoogle Scholar
  93. 93.
    Familial associations in sarcoidosis. A report to the Research Committee of the British Thoracic and Tuberculosis Association. Tubercle. 1973;54(2):87–98.Google Scholar
  94. 94.
    Brewerton DA, Cockburn C, James DC, James DG, Neville E. HLA antigens in sarcoidosis. Clin Exp Immunol. 1977;27(2):227–9.PubMedGoogle Scholar
  95. 95.
    Voorter CE, Amicosante M, Berretta F, Groeneveld L, Drent M, van den Berg-Loonen EM. HLA class II amino acid epitopes as susceptibility markers of sarcoidosis. Tissue Antigens. 2007;70(1):18–27.PubMedGoogle Scholar
  96. 96.
    Schurmann M, Reichel P, Muller-Myhsok B, Schlaak M, Muller-Quernheim J, Schwinger E. Results from a genome-wide search for predisposing genes in sarcoidosis. Am J Respir Crit Care Med. 2001;164(5):840–6.PubMedGoogle Scholar
  97. 97.
    Iannuzzi MC, Iyengar SK, Gray-McGuire C, Elston RC, Baughman RP, Donohue JF, et al. Genome-wide search for sarcoidosis susceptibility genes in African Americans. Genes Immun. 2005;6(6):509–18.PubMedGoogle Scholar
  98. 98.
    Valentonyte R, Hampe J, Huse K, Rosenstiel P, Albrecht M, Stenzel A, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet. 2005;37(4):357–64.PubMedGoogle Scholar
  99. 99.
    Rybicki BA, Walewski JL, Maliarik MJ, Kian H, Iannuzzi MC. The BTNL2 gene and sarcoidosis susceptibility in African Americans and Whites. Am J Hum Genet. 2005;77(3):491–9.PubMedGoogle Scholar
  100. 100.
    Gray-McGuire C, Sinha R, Iyengar S, Millard C, Rybicki BA, Elston RC, et al. Genetic characterization and fine mapping of susceptibility loci for sarcoidosis in African Americans on chromosome 5. Hum Genet. 2006;120(3):420–30.PubMedGoogle Scholar
  101. 101.
    Piotrowski WJ, Gorski P, Pietras T, Fendler W, Szemraj J. The selected genetic polymorphisms of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis. Med Sci Monit. 2011;17(10):CR598–607.PubMedGoogle Scholar
  102. 102.
    Rybicki BA, Sinha R, Iyengar S, GrayMcGuire C, Elston RC, Iannuzzi MC, et al. Genetic linkage analysis of sarcoidosis phenotypes: the sarcoidosis genetic analysis (SAGA) study. Genes Immun. 2007;8(5):379–86.PubMedGoogle Scholar
  103. 103.
    Veltkamp M, van Moorsel CH, Rijkers GT, Ruven HJ, Grutters JC. Genetic variation in the Toll-like receptor gene cluster (TLR10-TLR1-TLR6) influences disease course in sarcoidosis. Tissue Antigens. 2012;79(1):25–32.PubMedGoogle Scholar
  104. 104.
    Pabst S, Bradler O, Gillissen A, Nickenig G, Skowasch D, Grohe C. Toll-like receptor-9 polymorphisms in sarcoidosis and chronic obstructive pulmonary disease. Adv Exp Med Biol. 2013;756:239–45.PubMedGoogle Scholar
  105. 105.
    Scadding JG. Prognosis of intrathoracic sarcoidosis In England. BMJ. 1961;4:1165.Google Scholar
  106. 106.
    Rohatgi PK, Schwab LE. Primary acute pulmonary cavitation in sarcoidosis. AJR Am J Roentgenol. 1980;134(6):1199–203.PubMedGoogle Scholar
  107. 107.
    Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149–73.PubMedGoogle Scholar
  108. 108.
    Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med. 1983;52(208):525–33.PubMedGoogle Scholar
  109. 109.
    Hillerdal G, Nou E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis. 1984;130(1):29–32.PubMedGoogle Scholar
  110. 110.
    Kauffman CA. Quandary about treatment of aspergillomas persists. Lancet. 1996;347(9016):1640.PubMedGoogle Scholar
  111. 111.
    Khan MA, Dar AM, Kawoosa NU, Ahangar AG, Lone GN, Bashir G, et al. Clinical profile and surgical outcome for pulmonary aspergilloma: nine year retrospective observational study in a tertiary care hospital. Int J Surg. 2011;9(3):267–71.PubMedGoogle Scholar
  112. 112.
    Israel HL, Lenchner GS, Atkinson GW. Sarcoidosis and aspergilloma. The role of surgery. Chest. 1982;82(4):430–2.PubMedGoogle Scholar
  113. 113.
    Regnard JF, Icard P, Nicolosi M, Spagiarri L, Magdeleinat P, Jauffret B, et al. Aspergilloma: a series of 89 surgical cases. Ann Thorac Surg. 2000;69(3):898–903.PubMedGoogle Scholar
  114. 114.
    Garvey J, Crastnopol P, Weisz D, Khan F. The surgical treatment of pulmonary aspergillomas. J Thorac Cardiovasc Surg. 1977;74(4):542–7.PubMedGoogle Scholar
  115. 115.
    Kaestel M, Meyer W, Mittelmeier HO, Gebhardt C. Pulmonary aspergilloma – clinical findings and surgical treatment. Thorac Cardiovasc Surg. 1999;47(5):340–5.PubMedGoogle Scholar
  116. 116.
    Massard G, Roeslin N, Wihlm JM, Dumont P, Witz JP, Morand G. Pleuropulmonary aspergilloma: clinical spectrum and results of surgical treatment. Ann Thorac Surg. 1992;54(6): 1159–64.PubMedGoogle Scholar
  117. 117.
    Campbell JH, Winter JH, Richardson MD, Shankland GS, Banham SW. Treatment of pulmonary aspergilloma with itraconazole. Thorax. 1991;46(11):839–41.PubMedGoogle Scholar
  118. 118.
    De Beule K, De Doncker P, Cauwenbergh G, Koster M, Legendre R, Blatchford N, et al. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses. 1988;31(9):476–85.PubMedGoogle Scholar
  119. 119.
    Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol. 1990;23(3 Pt 2):607–14.PubMedGoogle Scholar
  120. 120.
    Hargis JL, Bone RC, Stewart J, Rector N, Hiller FC. Intracavitary amphotereicin B in the treatment of symptomatic pulmonary aspergillomas. Am J Med. 1980;68(3):389–94.PubMedGoogle Scholar
  121. 121.
    Hammerman KJ, Sarosi GA, Tosh FE. Amphotericin B in the treatment of saprophytic forms of pulmonary aspergillosis. Am Rev Respir Dis. 1974;109(1):57–62.PubMedGoogle Scholar
  122. 122.
    Mossi F, Maroldi R, Battaglia G, Pinotti G, Tassi G. Indicators predictive of success of embolisation: analysis of 88 patients with haemoptysis. Radiol Med. 2003;105(1-2):48–55.PubMedGoogle Scholar
  123. 123.
    Shin BS, Jeon GS, Lee SA, Park MH. Bronchial artery embolisation for the management of haemoptysis in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2011;15(8): 1093–8.PubMedGoogle Scholar
  124. 124.
    Uflacker R, Kaemmerer A, Neves C, Picon PD. Management of massive hemoptysis by bronchial artery embolization. Radiology. 1983;146(3):627–34.PubMedGoogle Scholar
  125. 125.
    Chun JY, Belli AM. Immediate and long-term outcomes of bronchial and non-bronchial systemic artery embolisation for the management of haemoptysis. Eur Radiol. 2010;20(3):558–65.PubMedGoogle Scholar
  126. 126.
    Lee KS, Kim HT, Kim YH, Choe KO. Treatment of hemoptysis in patients with cavitary aspergilloma of the lung: value of percutaneous instillation of amphotericin B. AJR Am J Roentgenol. 1993;161(4):727–31.PubMedGoogle Scholar
  127. 127.
    Shapiro MJ, Albelda SM, Mayock RL, McLean GK. Severe hemoptysis associated with pulmonary aspergilloma. Percutaneous intracavitary treatment. Chest. 1988;94(6):1225–31.PubMedGoogle Scholar
  128. 128.
    Rumbak M, Kohler G, Eastrige C, Winer-Muram H, Gavant M. Topical treatment of life threatening haemoptysis from aspergillomas. Thorax. 1996;51(3):253–5.PubMedGoogle Scholar
  129. 129.
    Munk PL, Vellet AD, Rankin RN, Muller NL, Ahmad D. Intracavitary aspergilloma: transthoracic percutaneous injection of amphotericin gelatin solution. Radiology. 1993;188(3):821–3.PubMedGoogle Scholar
  130. 130.
    Giron J, Poey C, Fajadet P, Sans N, Fourcade D, Senac JP, et al. CT-guided percutaneous treatment of inoperable pulmonary aspergillomas: a study of 40 cases. Eur J Radiol. 1998;28(3):235–42.PubMedGoogle Scholar
  131. 131.
    Jackson M, Flower CD, Shneerson JM. Treatment of symptomatic pulmonary aspergillomas with intracavitary instillation of amphotericin B through an indwelling catheter. Thorax. 1993;48(9):928–30.PubMedGoogle Scholar
  132. 132.
    Kravitz JN, Berry MW, Schabel SI, Judson MA. A modern series of percutaneous intracavitary instillation of amphotericin B for the treatment of severe hemoptysis from pulmonary aspergilloma. Chest. 2013;143(5):1414–21.PubMedGoogle Scholar
  133. 133.
    Freiman DG. Sarcoidosis. N Engl J Med. 1948;239:664.PubMedGoogle Scholar
  134. 134.
    Ross RJ, Empey DW. Bilateral spontaneous pneumothorax in sarcoidosis. Postgrad Med J. 1983;59(688):106–7.PubMedGoogle Scholar
  135. 135.
    Froudarakis ME, Bouros D, Voloudaki A, Papiris S, Kottakis Y, Constantopoulos SH, et al. Pneumothorax as a first manifestation of sarcoidosis. Chest. 1997;112(1):278–80.PubMedGoogle Scholar
  136. 136.
    Sharma OP. Sarcoidosis: unusual pulmonary manifestations. Postgrad Med. 1977;61(3):67–73.PubMedGoogle Scholar
  137. 137.
    Schoenenberger RA, Haefeli WE, Weiss P, Ritz RF. Timing of invasive procedures in therapy for primary and secondary spontaneous pneumothorax. Arch Surg. 1991;126(6):764–6.PubMedGoogle Scholar
  138. 138.
    Mathur R, Cullen J, Kinnear WJ, Johnston ID. Time course of resolution of persistent air leak in spontaneous pneumothorax. Respir Med. 1995;89(2):129–32.PubMedGoogle Scholar
  139. 139.
    Rinaldi S, Felton T, Bentley A. Blood pleurodesis for the medical management of pneumothorax. Thorax. 2009;64(3):258–60.PubMedGoogle Scholar
  140. 140.
    Ando M, Yamamoto M, Kitagawa C, Kumazawa A, Sato M, Shima K, et al. Autologous blood-patch pleurodesis for secondary spontaneous pneumothorax with persistent air leak. Respir Med. 1999;93(6):432–4.PubMedGoogle Scholar
  141. 141.
    Aihara K, Handa T, Nagai S, Tanizawa K, Watanabe K, Harada Y, et al. Efficacy of blood-patch pleurodesis for secondary spontaneous pneumothorax in interstitial lung disease. Intern Med. 2011;50(11):1157–62.PubMedGoogle Scholar
  142. 142.
    Travaline JM, McKenna Jr RJ, De Giacomo T, Venuta F, Hazelrigg SR, Boomer M, et al. Treatment of persistent pulmonary air leaks using endobronchial valves. Chest. 2009;136(2):355–60.PubMedGoogle Scholar
  143. 143.
    Greer T, Pastis N, Strange C, Huggins J. Sarcoidosis with secondary spontaneous pneumothorax treated with endobronchial valves. Chest. 2012;142:874A.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Division of Pulmonary, Critical Care, Allergy, and Sleep MedicineMedical University of South CarolinaCharlestonUSA

Personalised recommendations